Second Quarter 2024 Financial Results & Business Update July 24, 2024 Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations with respect to its current and future financial, commercial and operating performance, business plans o ...

Financial Performance - Second quarter revenues reached $399.1 million, a decrease from $617.4 million in the same period last year[1][3] - Total revenues for the three months ended June 30, 2024, were $399,131,000, a decrease of 35.4% compared to $617,397,000 for the same period in 2023[26] - For the six months ended June 30, 2024, total revenues were $749,503,000, down 17.2% from $904,992,000 in the same period of 2023[29] - Operating income for the three months ended June 30, 2024, was $109,883,000, down 60.1% from $281,269,000 in the same period of 2023[26] - Net income from continuing operations for the three months ended June 30, 2024, was $94,658,000, a decline of 66.1% compared to $279,101,000 in the prior year[27] - Net income from continuing operations for the six months ended June 30, 2024, was $133,606,000, a decrease of 50% compared to $267,051,000 in the prior year[31] - The company reported a basic GAAP earnings per share from continuing operations of $0.79 for the six months ended June 30, 2024, down from $1.61 in the same period of 2023[29] Product Sales - Proprietary product net sales increased approximately 16% year-over-year, totaling $269.3 million compared to $231.5 million[1][3] - LYBALVI revenues grew 52% year-over-year to $71.4 million, with total prescriptions increasing by 44%[6] - ARISTADA revenues were $86.0 million, with new to brand prescriptions growing 6% sequentially[7] - VIVITROL revenues increased by 10% year-over-year to $111.9 million, driven by the alcohol dependence indication[8] - Product sales, net, increased to $269,273,000 for the three months ended June 30, 2024, up from $231,477,000 in the prior year, representing a growth of 16.3%[26] Income and Expenses - GAAP net income from continuing operations was $94.7 million, with diluted GAAP earnings per share of $0.55[1][4] - Non-GAAP net income from continuing operations for the three months ended June 30, 2024, was $123,442,000, compared to $134,308,000 in the same period of 2023, reflecting a decrease of 8.7%[28] - Total expenses for the three months ended June 30, 2024, were $289,248,000, down 13.9% from $336,128,000 in the same period of 2023[26] - EBITDA from continuing operations for the three months ended June 30, 2024, was $118,594,000, a decrease of 60.3% from $299,068,000 in the same period of 2023[27] Cash and Investments - Cash, cash equivalents, and total investments amounted to $962.5 million as of June 30, 2024, up from $807.8 million at the end of March 2024[11] - Cash, cash equivalents, and total investments reached $962,520 thousand, up from $813,378 thousand at the end of 2023[33] Shareholder Actions - The company repurchased approximately 3.5 million ordinary shares for a total of $84.7 million during the second quarter[12] - Total shareholders' equity increased to $1,284,005 thousand, compared to $1,202,686 thousand at the end of the previous year[33] Research and Development - The company announced positive topline results from the phase 1b study of ALKS 2680 for narcolepsy, with further studies initiated[14][15] - Research and development expenses for the latest quarter were $3,913 thousand, up from $2,516 thousand in the previous quarter[34] Future Outlook - Alkermes reiterated its financial expectations for 2024, maintaining a strong operational focus on its commercial portfolio and neuroscience development pipeline[13][14] - The company intends to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, in July 2024[33]

DUBLIN, July 17, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to discuss the company's second quarter financial results.The webcast player and accompanying slides may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the webcas ...

The market expects Alkermes (ALKS) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the s ...

— Orexin 2 Receptor Agonist ALKS 2680 Demonstrated Clinically Meaningful and Statistically Significant Improvements from Baseline in Mean Sleep Latency Compared to Placebo at All Doses Tested —— ALKS 2680 Was Generally Well Tolerated at All Doses Tested —— Vibrance-1 Phase 2 Study of ALKS 2680 in Patients With Narcolepsy Type 1 Is Ongoing —DUBLIN, June 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from the full narcolepsy type 1 (NT1) cohort of a phase 1b, proof-of-concept stu ...

Core Insights - Alkermes plc is set to present three posters related to ALKS 2680 at the SLEEP 2024 conference, highlighting its investigational oral orexin 2 receptor agonist for narcolepsy treatment [1][3] Group 1: ALKS 2680 Development - ALKS 2680 is being developed as a once-daily treatment for narcolepsy, targeting the orexin 2 receptor to improve wakefulness and control cataplexy [6][8] - The company will present data from a phase 1b study involving 10 patients with narcolepsy type 1, focusing on safety and pharmacodynamic efficacy [1][3] - The Vibrance-1 study is a phase 2 clinical trial comparing ALKS 2680 to placebo in patients with narcolepsy type 1, recently initiated following proof-of-concept data [3][7] Group 2: Patient Insights - Findings from qualitative interviews with 22 patients (12 with narcolepsy type 1 and 10 with type 2) will be presented, detailing the disease's impact on various life aspects [2][3] - The interviews aimed to uncover the burden of narcolepsy on work, mental health, daily activities, and relationships [2][3] Group 3: Presentation Details - The presentations at SLEEP 2024 include specific poster sessions on the safety and pharmacodynamic effects of ALKS 2680, study design for Vibrance-1, and patient perspectives on living with narcolepsy [4][5]

As we delve deeper into 2024, biotech stocks are commanding the attention of growth-focused investors. Despite facing volatility and regulatory challenges in recent years, biotech is poised for a resurgence. Breakthroughs in personalized medicine and gene editing technologies are driving biotech forward.The global biotechnology market was valued at $1.0 trillion in 2022 and is projected to reach $3.6 trillion by 2032. Increasing demand for personalized medicine and advancements in genetic engineering will d ...

Core Viewpoint - Alkermes plc reported adjusted earnings of 44 cents per share for Q1 2024, missing the Zacks Consensus Estimate of 59 cents, but showing an increase from 18 cents in the same quarter last year [1] Revenue Performance - Total revenues for Alkermes reached $350.4 million, a 21.8% increase year-over-year, but fell short of the Zacks Consensus Estimate of $360 million [1] - Vivitrol sales increased by approximately 1% year-over-year to $97.7 million, missing the Zacks Consensus Estimate of $99 million [2] - Aristada sales decreased by 1.5% year-over-year to $78.9 million, also missing the Zacks Consensus Estimate of $81 million [2] - Lybalvi generated sales of $57 million, up 50% year-over-year, slightly exceeding the Zacks Consensus Estimate [3] - Total manufacturing and royalty revenues increased by 60.4% year-over-year to $116.8 million, driven by reinstated royalties on long-acting Invega products [3] Expense Overview - Research and development expenses totaled $67.6 million, up nearly 6% year-over-year due to increased investments in pipeline development for ALKS 2680 [3] - Selling, general and administrative expenses reached $179.7 million, a 7.1% increase year-over-year, attributed to continued investment for Lybalvi's launch [4] Financial Position - As of March 31, 2024, Alkermes had cash and cash equivalents of $807.8 million, a slight decrease from $813.4 million as of December 31, 2023 [4] 2024 Guidance - Alkermes reiterated its revenue guidance for 2024, expecting total revenues between $1.5 billion and $1.6 billion [6] - Vivitrol net sales are projected to be between $410 million and $430 million, Aristada sales between $340 million and $360 million, and Lybalvi's net sales between $275 million and $295 million [6] - Research and development expenses are anticipated to be between $225 million and $255 million, while selling, general and administrative expenses are projected to be between $625 million and $655 million [6] Recent Developments - Alkermes announced positive top-line data from a phase Ib study for ALKS 2680, showing significant improvements in sleep latency for narcolepsy treatment [7] - The company initiated the Vibrance-1 phase II study for ALKS 2680 in patients with narcolepsy type 1 [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other jurisdiction of incorporation or o ...

Alkermes plc (NASDAQ:ALKS) Q1 2024 Earnings Conference Call May 1, 2024 8:00 AM ET Company Participants Sandra Coombs - Senior Vice President, Corporate Affairs and Investor Relations Blair Jackson - Chief Operating Officer Todd Nichols - Chief Commercial Officer Richard Pops - Chief Executive Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald David Amsellem - Piper Sandler Joel Beatty - Baird Umer Raffat - Evercore ISI Jason Gerberry - Bank of America Uy Ear - Mizuho Securities Jessica ...